Evidence-Based Complementary and Alternative Medicine

Evidence-Based Complementary and Alternative Medicine / 2013 / Article

Research Article | Open Access

Volume 2013 |Article ID 413092 | https://doi.org/10.1155/2013/413092

Wei Xie, Yun Hong Yu, Yong Ping Du, Yun Yan Zhao, Chang Zheng Li, Lin Yu, Jian Hong Duan, Jun Ling Xing, "Saikosaponin a Enhances Transient Inactivating Potassium Current in Rat Hippocampal CA1 Neurons", Evidence-Based Complementary and Alternative Medicine, vol. 2013, Article ID 413092, 10 pages, 2013. https://doi.org/10.1155/2013/413092

Saikosaponin a Enhances Transient Inactivating Potassium Current in Rat Hippocampal CA1 Neurons

Academic Editor: Ke Liu
Received16 Nov 2012
Accepted01 Jan 2013
Published21 Feb 2013


Saikosaponin a (SSa), a main constituent of the Chinese herb Bupleurum chinense DC., has been demonstrated to have antiepileptic activity. Recent studies have shown that SSa could inhibit NMDA receptor current and persistent sodium current. However, the effects of SSa on potassium (K+) currents remain unclear. In this study, we tested the effect of SSa on 4AP-induced epileptiform discharges and K+ currents in CA1 neurons of rat hippocampal slices. We found that SSa significantly inhibited epileptiform discharges frequency and duration in hippocampal CA1 neurons in the 4AP seizure model in a dose-dependent manner with an of 0.7 μM. SSa effectively increased the amplitude of and , significantly negative-shifted the activation curve, and positive-shifted steady-state curve of . However, SSa induced no significant changes in the amplitude and activation curve of . In addition, SSa significantly increased the amplitude of 4AP-sensitive K+ current, while there was no significant change in the amplitude of TEA-sensitive K+ current. Together, our data indicate that SSa inhibits epileptiform discharges induced by 4AP in a dose-dependent manner and that SSa exerts selectively enhancing effects on . These increases in may contribute to the anticonvulsant mechanisms of SSa.

1. Introduction

Saikosaponin a (SSa) is the primary active constituent derived from Bupleurum chinense DC. (Umbelliferae) [1]. The molecular formula of SSa is C42H68O13 with a molecular weight of 780.98. The molecular structure of SSa is shown in Figure 1. In clinical and laboratory studies, it has been reported that SSa has a variety of pharmacological benefits, including anti-inflammatory, immunomodulatory, and antibacterial activities [2]. In recent years, we have found that SSa demonstrates antiepileptic activities in a variety of in vivo seizure models including the pentylenetetrazole kindling model, the maximal-electroshock-(MES-) induced seizure model and the Li-Pilocarpine-induced refractory epilepticus [35]. Our recent studies have shown that SSa inhibits spontaneous recurrent epileptiform discharges (SREDs) and continuous tonic high-frequency epileptiform bursts (SE) induced by applying Mg2+-free solution in hippocampal neuronal cultured models of acquired epilepsy and status epilepticus [6]. In addition, SSa could inhibit NMDA receptor current and persistent sodium current in cultured hippocampal neurons [6]. However, we have also found that the half-maximum effective dose of SSa required to inhibit SE is larger than that required to inhibit SREDs in the low-Mg2+ seizure model in vitro [6]. This evidence suggests that SSa anticonvulsant activities may result from other mechanisms, in addition to the inhibitions of NMDA receptor current and persistent sodium current.

Under physiological conditions, voltage-gated potassium (K+) currents are key regulators of neuronal excitability [7], such as resting membrane potential, action potential waveform, and firing frequency [8, 9]. Alterations in their electrical function are related to hyperexcitability and epilepsy [10, 11]. Several animal models of epilepsy have been developed by using K+ channel blockers, such as 4-aminopyridine (4AP) [12], dendrotoxin I [13], tityustoxin-K, and pandinustoxin-K [14]. In addition, mice with induced deletions of various K+ current genes exhibit seizures [15, 16]. K+ currents were decreased in hippocampal CA1 pyramidal neuron dendrites in several animal models of seizure [17, 18]. Drugs that enhance K+ currents activity possess antiepileptic action [19, 20]. Thus, K+ currents may play an active role in controlling epileptic synchronization [21, 22].

In hippocampal CA1 neurons, the total voltage-gated outward K+ current ( ) consists of two main types of voltage-gated K+ currents, a transient inactivating K+ current ( ) and a delayed rectifier K+ current ( ) [8, 9]. As is transient, repolarization is mainly related to , while plays an important role in repetitive firing and back propagation of action potential into dendrites [23]. and play major roles in regulating the excitability of neurons [7]. Changes in their kinetic properties can alter neuronal excitability and electrical function [24].

In the present study, we used whole-cell patch-clamp recordings to evaluate the anticonvulsant effects of SSa on 4AP-induced epileptiform discharges and to investigate the dynamic and pharmacological modulation effects of SSa on K+ currents in CA1 neurons of rat hippocampal slice. Using whole-cell recording techniques, we found that SSa inhibited epileptiform discharges induced by 4AP in a dose-dependent manner and that SSa exerts selectively increasing effects on but not in hippocampal CA1 neurons. The increasing effects on may contribute to the anticonvulsant mechanisms of SSa.

2. Materials and Methods

2.1. Materials

Saikosaponin a (purity > 98%, obtained from Shanghai Institute of Pharmaceutical Industry, Shanghai, China) was dissolved in DMSO at a concentration of 100 mM as a stock solution and stored at −20°C. Working solutions were prepared before each experiment, and the final DMSO concentration did not exceed 0.1% throughout the study. Recordings were performed in the presence and absence of SSa or the vehicle. Other reagents were purchased from Sigma (St. Louis, MO, USA).

2.2. Slice Preparation

Sprague-Dawley rats (25–50 days old) were provided by the Animal Center of the Fourth Military Medical University. The animals were housed and handled in strict accordance with the guidelines of the institutional and national Committees of Animal Use and Protection. The protocol was approved by the Committee on the Ethics of Animal Experiments of the Fourth Military Medical University. Hippocampal slices were cut in this study as previously described [25], with some modifications. Rats were anesthetized with isoflurane and decapitated. The brains were rapidly removed and placed in ice-cold Ringer’s solution that contained (in mM) 124 NaCl, 2.5 KCl, 1.25 NaH2PO4, 2 MgSO4, 25 NaHCO3, 0.5 CaCl2, and 10 glucose and was gassed with 95% O2/5% CO2 mixture to attain a pH of 7.2–7.4. Transverse brain slices (300–350 μm in thickness) that included the entire hippocampus were cut with a Vibratome (VT1000S, Leica, Germany) and left undisturbed in an incubation chamber for 1 h for stabilization at room temperature (21–24°C) in artificial cerebrospinal fluid (ACSF) that contained (in mM) 124 NaCl, 2.5 KCl, 1.25 NaH2PO4, 2 MgSO4, 25 NaHCO3, 2 CaCl2, and 10 glucose and was gassed with 95% O2/5% CO2.

2.3. Electrophysiological Recordings

Hippocampal CA1 pyramidal neurons were visualized with an Olympus BX51WI upright microscope (Olympus Optical Co., Center Valley, PA, USA) equipped with a 40X water-immersion lens and optics for differential interference contrast and infrared (DIC-IR). Recorded cells were identified as CA1 hippocampal pyramidal neurons according to their placement in the pyramidal layer and their electrophysiological properties [26]. Patch electrodes with a resistance of 5–8 MΩ in the bath were pulled on a microelectrode puller (P97, Sutter Instruments, USA). The epileptiform activity was recorded in whole-cell current-clamp mode and potassium currents were collected in whole-cell voltage-clamp mode. Whole-cell current- and voltage-clamp recordings were carried out using an Axopatch 700B amplifier (Axon Instruments, Foster City, CA). The data were transferred to a PC using a Digidata 1322A (Axon Instruments) interface and acquired using pCLAMP 9 (Axon Instruments) software. All junction potentials were corrected online by adjusting the pipette offset using the 700B Commander software (Molecular Devices).

For whole-cell current-clamp recordings, slices were placed in an immersion recording chamber and superfused (1.5 mL/min) with gassed ACSF at 32-33°C. The recording pipette solution contained (in mM) 140 K gluconate, 5 NaCl, 1 CaCl2, 2 MgCl2, 11 EGTA, 10 HEPES, 2 Mg-ATP, and 0.3 Na-GTP, pH 7.4 with KOH. To induce epileptiform events, slices were superfused with ACSF containing 100 mM 4AP for 20–40 min [27]. Recordings were obtained from hippocampal CA1 neurons. Once epileptiform discharges were present and stable for 20–40 min (at least three epileptiform discharges), SSa was superfused concurrent with the convulsant treatment for 20–40 min to evaluate the inhibition of epileptiform activities. Finally, a 20–40 min superfusion of ACSF contained 100 mM 4AP was performed as a washout for observations of any persistent effects. The data were digitized at 2 kHz.

To record K+ currents, 1 μM tetrodotoxin (TTX) and 200 μM cadmium chloride (CdCl2) were added into the ACSF to block Na+ and Ca2+ currents. After the establishment of a whole-cell voltage-clamp configuration, the cells were allowed to stabilize for 3–5 min before starting pulse protocols to record the currents as control. After the currents were stable, SSa (1 μM) was added into the ACSF to examine its effects on the properties of voltage-gated K+ currents ( , and ) in rat hippocampal CA1 neurons. Modifications of 4AP-sensitive and TEA-sensitive K+ currents by SSa were also observed. Signals were low-pass filtered at 2 kHz and digitized at 10 kHz. Fast and slow capacitances were neutralized, and the series resistance was compensated (50–70%) and periodically monitored. Capacitance transients and leakage currents linear with voltage were subtracted using a P/4 voltage protocol. Recordings were made at room temperature (22–24°C).

2.4. Statistical Analysis

All results were expressed as the mean ± SEM. Statistical analysis was performed using Statistical Product and Service Solutions (SPSS) software (paired t-test, unpaired t-test, or one-way ANOVA). Values of were considered to be significant. The data were plotted using Origin 8.0.

Changes of epileptiform discharges frequency and duration were quantified. For concentration-response analysis, the percentage inhibition of epileptiform discharges frequency was determined at different concentrations of SSa. The concentration-response curve was obtained by fitting the experimental data with a logistic equation with variable slope (Hill coefficient): , where is the response in the presence of drug, is the maximal response in the absence of drug, D is the drug concentration, is the concentration of drug producing a half-maximal inhibition of the response, and is the Hill coefficient. Fit estimates were calculated using Marquardt nonlinear least squares algorithms. Steady-state activation and inactivation curves were fitted with the Boltzmann equation: , where is normalized current, is the membrane potential of the preceding voltage step, is the potential for half-maximal activation/inactivation, and is the slope factor.

3. Results

3.1. Effects of SSa on Epileptiform Discharges Induced by 4AP in Hippocampal CA1 Neurons in Hippocampus Slices

The in vitro hippocampal seizure model induced by 100 μM 4AP was used to evaluate the anticonvulsant activities of SSa with whole-cell current-clamp recordings [27]. The anticonvulsant effects of SSa were observed at doses as low as 0.1 μM and as high as 4 μM. The percentage inhibition of epileptiform discharges frequency and duration was determined to evaluate the effectiveness of SSa.

Superfusion of 100 μM 4AP for 20–40 min caused a prominent increase in the duration of the action potential due to a slow repolarization phase (Figures 2(A)-(a)). The ictal discharges phase consisted of tonic and clonic components and was followed by interictal events. During the ictal tonic phase, the membrane depolarized to −20 mV  mV ( ) and gradually recovered within 5 s of the ictal clonic phase to the control value of −  mV ( ). Therefore, epileptiform discharges can be generated in the intact preparation by 4AP with all the phases that are observed in vivo. After coapplication of SSa (1 μM) with 100 μM 4AP for 20–40 min, the epileptiform discharges duration was significantly decreased from  s ( ) in 4AP solution to  s ( ; paired t-test; ; Figures 2(A)-(b), (c)). The epileptiform discharges frequency was significantly decreased by % ( ) by SSa at dose of 1 μM (Figure 2 ). Washing out the drug with ACSF containing 100 μM 4AP >30 min, the epileptiform discharges duration and frequency returned to the values observed before SSa. The log concentration-response curve of percentage inhibition of epileptiform discharges frequency showed that SSa inhibited epileptiform activities in a concentration-dependent manner and that the was 0.70 μM (Figure 2 ).

3.2. Effects of SSa on , , and

The voltage protocols in Figures 3 and 4 were used for kinetic separation of the outward K+ currents. To elicit , the holding potential was −50 mV and a 300 ms hyperpolarizing prepulse to −120 mV was followed by a series of 400 ms steps from −60 to +60 mV in 10 mV increments, delivered every 10 s (Figure 3(a), top of right panel). To elicit , a similar protocol was used, but a 100 ms interval at −40 mV was inserted after the prepulse (Figure 3(a), middle of right panel). was calculated by point-by-point subtracting from [28]. Figure 2 shows typical traces of three outward voltage-gated K+ currents ( , , and ) before (control, left panels) and after (middle panels) administration of 1 μM SSa. Normalizing the peak current, SSa produced only a small increase in the amplitude of , by % ( ; paired t-test; ; Figure 3(b)) and did not induce a significant change in the amplitude of ( ; paired t-test; ). SSa at 1 μM caused an obvious increase in the amplitude of after subtracting from , by % ( ; paired t-test; ; Figure 3(b)).

3.3. Effects of SSa on I-V Relationship and the Activation Kinetics of , , and

The I-V relationships for , and under control condition and after application of 1 μM SSa are shown in Figures 4(a), 4(b), and 4(c), and the steady-state activation curves for , , and are shown in Figures 4(d), 4(e), and 4(f). The increasing effects of SSa on the amplitude of and were voltage dependent. As the membrane potential was stepped to more depolarizing values, the amplitude-increasing effects of SSa increased nominally (Figures 4(a), 4(c)), while there was no significant change in (Figure 4(b)). There was no significant change in voltage for half-maximal activation ( ) of between control and SSa-treated preparations ( versus  mV, respectively; ; paired t-test; ), nor did the slope factor ( ) change ( versus , respectively; ; paired t-test; ). Similarly, no significant change was observed in for in control and SSa-treated preparations ( versus  mV, respectively; ; paired t-test; ) as well as ( versus , respectively; ; paired t-test; ). SSa caused a significant change in for ( in control versus  mV in SSa; ; paired t-test; ) with ( versus , respectively; ; paired t-test; ). The steady-state activation curves showed that SSa significantly negative-shifted the voltage dependence of the activation of with no change in slope factor (Figure 4(f)).

3.4. Effects of SSa on the Steady-State Inactivation Properties of

Steady-state inactivation was studied based on the double-pulse protocols as follow. Neurons were held at −50 mV and currents were elicited with an 80 ms test pulse to +50 mV preceded by 120 ms prepulses to potentials between −90 mV and +10 mV (Figure 5(a), bottom panel). The peak amplitudes of were normalized and plotted versus the prepulse potentials. The curves were fitted with the Boltzmann equation, as described in Materials and Methods: . Application of 1 μM SSa caused a significant depolarizing shift of the voltage-dependent steady-state inactivation of (Figure 5(b)). of changed from −  mV in control to −  mV in SSa ( ; paired t-test; ), with the slope factor, , values of and 12. , respectively ( ; paired t-test; ).

3.5. Effects of SSa on 4AP-Sensitive and TEA-Sensitive K+ Current

is sensitive to high concentration of 4AP, whereas is blocked by TEA [29]. Hence, we further established whether SSa was capable of modulating one or both of these two pharmacologically distinct, outward K+ currents. Outward K+ currents were generated by a depolarizing pulse +10 mV delivered from a holding potential of −80 mV (Figure 6(a), right of top panel). 4AP-sensitive (Figure 6(a), middle panel) and TEA-sensitive K+ current (Figure 6(a), bottom panel) were obtained by application of 20 mM TEA or 4 mM 4AP, respectively. SSa enhanced a transient, 4AP-sensitive outward K+ current in the presence of 20 mM TEA by % (normalized with control; ; paired-t test; ; Figure 6(b)), while it did not induce a significant modification in the amplitude of a late, TEA-sensitive K+ current after application of 4 mM 4AP (Figure 6(b)).

4. Discussion

The present study indicated, for the first time, that SSa inhibited epileptiform events induced by 100 μM 4AP in rat CA1 neurons in hippocampus slices in a dose-dependent manner. In the 4AP seizure model, SSa showed long-lasting effects by decreasing the seizure amplitude for >30 min with washout, similar to other anticonvulsants such as carbamazepine [30]. In recent studies, we have found that SSa inhibited epileptiform discharges evoked by low-Mg2+ solution in hippocampal neuronal cultured models of acquired epilepsy and status epilepticus [6]. These results demonstrate that SSa has anticonvulsant properties in both the 4AP seizure model and the low-Mg2+ seizure model. As is known, some anticonvulsants appear to be more effective in some models of seizures than in others. For instance, when examining the efficacy on refractory seizures induced by low Mg2+ in the immature corticohippocampal formation in vitro, some drugs such as valproate suppress epileptiform activity, whereas ethosuximide, gabapentin, phenytoin, and topiramate are ineffective [31]. Valproate, and not phenytoin or carbamazepine, abolishes epileptiform activity induced by 4AP in entorhinal cortex-hippocampal slices [32]. These results may imply SSa as a novel effective treatment for epilepsy.

The inhibitions of NMDA receptor current and persistent sodium current in cultured hippocampal neurons may be some anticonvulsant mechanisms of SSa [6]. While the results that the percentage inhibition of epileptiform discharges frequency at the same dose of SSa in 4AP-induced seizure were different from that in low-Mg2+-induced seizure, which led us to consider the possibility that the different sensitivities of these two types of epileptiform discharges to SSa are caused by an additional mechanism of action. As 4AP acts as a convulsant, resulting from the blockade of K+ channels [12], the modulation of K+ currents by SSa was attractive.

From further studies in rat hippocampal CA1 neurons, we found that SSa effectively increased the amplitude of and . SSa significantly shifted the activation curves of to negative potentials. In addition, SSa significantly positive-shifted the steady-state inactivation of . However, there were no significant effects of SSa on the amplitude and activation curves of , which might account for the result that the increasing potency of SSa was much stronger with regards to than . These results suggest that SSa has a selective modification effect on .

, prominent in hippocampal neurons, shows fast activation and relatively fast inactivation [8, 33]. It belongs to the threshold currents activated near the spiking threshold [34], and in this respect, it delays the action potential and controls the interspike interval during repetitive firing [29, 35]. regulates repetitive firing, which is obviously related to abnormal discharge [36, 37]. The reduction of will induce neuronal hyperexcitability and finally result in epilepsy [37, 38]. 4AP, dendrotoxin I, tityustoxin-K, or pandinustoxin-K are known to readily induce epileptiform discharges resulting from blockade of K+ channels [10, 12, 14]. In addition, recent evidence indicates that some epileptic syndromes occurring in both animals and humans are caused by mutations in K+ channel genes [15, 16]. In hippocampal tissue after Li-Pilocarpine-induced seizures, CA1 pyramidal neuron dendrites showed decreased availability of the due to transcriptional and posttranslational processes [39, 40]. has the property to selectively suppress rapid, large, and synchronized EPSPs inputs [41, 42]. It may thus limit the intensity of firing and reduce the duration of epileptiform discharges, which may be an important mechanism for the control of seizures. Indeed, several anticonvulsants have been shown to enhance including lamotrigine [43, 44], valproate [45], and carbamazepine [46]. Hence, the effects of SSa on reported here may be relevant for its anticonvulsant action.

can be completely blocked by high concentrations of 4AP, while is highly sensitive to TEA [29, 47]. We further evaluated the modulatory effect of SSa on 4AP-sensitive K+ current and TEA-sensitive K+ current, isolated pharmacologically. We found that SSa significantly increased the outward K+ current during application of 20 mM TEA, while there was no obvious change in the outward K+ current during application of 4 mM 4AP. This result suggests that SSa possesses a high affinity to 4AP-sensitive K+ current, which maybe consistent with the above finding that SSa selectively increased .

In conclusion, our results demonstrate that SSa exerts anticonvulsant properties by inhibiting 4AP-induced epileptiform discharges in CA1 neurons in rat hippocampus slices. Increase of , but not , by SSa may represent a mechanism by which SSa exerts anticonvulsant properties. However, several issues remain to be investigated in the future. First is the lack of functional data providing a direct link between K+ channel increase and direct indicators of the anticonvulsant properties of SSa. Second, studies on heterologously expressed genes encoding the ion channels responsible for and could be used to distinguish the effects of SSa. Third, studies evaluating the effects of SSa on other types K+ current, such as M-type K+ current, would be performed to investigate other anticonvulsant mechanisms of SSa.


SSa: Saikosaponin a
4AP: 4-aminopyridine
SREDs: Spontaneous recurrent epileptiform discharges
SE: Continuous tonic high-frequency epileptiform bursts
: Total voltage-gated outward current
: Transient inactivating current
: Delayed rectifier current
ACSF: Artificial cerebrospinal fluid.

Authors’ Contribution

W. Xie and Y. Hong Yu contributed equally to this work.


This work was supported by the National Science Foundation of China (no. 81173458); the National Science Foundation of Guangdong Province, China (no. S2011020003207); and the Ministry of education “Higher School Specialized Research Foundation” of China (no. 20114433110003).


  1. M. Ono, A. Yoshida, Y. Ito, and T. Nohara, “Phenethyl alcohol glycosides and isopentenol glycoside from fruit of Bupleurum falcatum,” Phytochemistry, vol. 51, no. 6, pp. 819–823, 1999. View at: Publisher Site | Google Scholar
  2. P. B. Bermejo Benito, M. J. Abad Martínez, A. M. Silván Sen et al., “In vivo and in vitro antiinflammatory activity of Saikosaponins,” Life Sciences, vol. 63, no. 13, pp. 1147–1156, 1998. View at: Publisher Site | Google Scholar
  3. Y. S. Huang, W. Xie, and B. T. Chen, “Effect of saikosaponins on epileptic rat electroenciphalogram,” Di Yi Jun Yi Da Xue Xue Bao, vol. 24, no. 12, pp. 1379–1381, 2004. View at: Google Scholar
  4. W. Xie, Y. Bao, L. J. Yu, G. N. Hou, and H. X. Tan, “Effect of saikosaponins on epileptic seizure and EEG in pentetrazole-induced chronic kindling rats,” Nan Fang Yi Ke Da Xue Xue Bao, vol. 26, no. 2, pp. 177–180, 2006. View at: Google Scholar
  5. W. Xie, C. X. Meng, G. J. Shi, S. Q. Fan, Y. Hong, and W. J. Chen, “Effect of saikosaponin-a on epileptic seizures in refractory epilepsy rats,” Journal of Tropical Medicine, no. 5, pp. 382–385, 2012. View at: Google Scholar
  6. Y.-H. Yu, W. Xie, Y. Bao, H.-M. Li, S.-J. Hu, and J.-L. Xing, “Saikosaponin a mediates the anticonvulsant properties in the HNC models of AE and SE by inhibiting NMDA receptor current and persistent sodium current,” PLoS ONE, vol. 7, no. 11, Article ID 50694, 2012. View at: Publisher Site | Google Scholar
  7. D. A. Hoffman, J. C. Magee, C. M. Colbert, and D. Johnston, “K+ channel regulation of signal propagation in dendrites of hippocampal pyramidal neurons,” Nature, vol. 387, no. 6636, pp. 869–875, 1997. View at: Publisher Site | Google Scholar
  8. J. F. Storm, “Potassium currents in hippocampal pyramidal cells,” Progress in Brain Research, vol. 83, pp. 161–187, 1990. View at: Google Scholar
  9. O. Pongs, T. Leicher, M. Berger et al., “Functional and molecular aspects of voltage-gated K+ channel β subunits,” Annals of the New York Academy of Sciences, vol. 868, pp. 344–355, 1999. View at: Publisher Site | Google Scholar
  10. R. A. Newitt, K. M. Houamed, H. Rehm, and B. L. Tempel, “Potassium channels and epilepsy: evidence that the epileptogenic toxin, dendrotoxin, binds to potassium channel proteins,” Epilepsy research Supplement, vol. 4, pp. 263–273, 1991. View at: Google Scholar
  11. I. Timofeev, F. Grenier, and M. Steriade, “Contribution of intrinsic neuronal factors in the generation of cortically driven electrographic seizures,” Journal of Neurophysiology, vol. 92, no. 2, pp. 1133–1143, 2004. View at: Publisher Site | Google Scholar
  12. P. A. Rutecki, F. J. Lebeda, and D. Johnston, “4-Aminopyridine produces epileptiform activity in hippocampus and enhances synaptic excitation and inhibition,” Journal of Neurophysiology, vol. 57, no. 6, pp. 1911–1924, 1987. View at: Google Scholar
  13. J. C. Velluti, A. Caputi, and O. Macadar, “Limbic epilepsy induced in the rat by dendrotoxin, a polypeptide isolated from the green mamba (Dendroaspis angusticeps) venom,” Toxicon, vol. 25, no. 6, pp. 649–657, 1987. View at: Google Scholar
  14. K. N. Juhng, T. G. Kokate, S. Yamaguchi et al., “Induction of seizures by the potent K+ channel-blocking scorpion venom peptide toxins tityustoxin-Kα and pandinustoxin-Kα,” Epilepsy Research, vol. 34, no. 2-3, pp. 177–186, 1999. View at: Publisher Site | Google Scholar
  15. S. L. Smart, V. Lopantsev, C. L. Zhang et al., “Deletion of the K(v)1.1 Potassium channel causes epilepsy in mice,” Neuron, vol. 20, no. 4, pp. 809–819, 1998. View at: Publisher Site | Google Scholar
  16. L. F. Barnwell, J. N. Lugo, W. L. Lee et al., “Kv4.2 knockout mice demonstrate increased susceptibility to convulsant stimulation,” Epilepsia, vol. 50, no. 7, pp. 1741–1751, 2009. View at: Publisher Site | Google Scholar
  17. P. A. Castro, E. C. Cooper, D. H. Lowenstein, and S. C. Baraban, “Hippocampal heterotopia lack functional Kv4.2 potassium channels in the methylazoxymethanol model of cortical malformations and epilepsy,” Journal of Neuroscience, vol. 21, no. 17, pp. 6626–6634, 2001. View at: Google Scholar
  18. E. Aronica, K. Boer, K. J. Doorn et al., “Expression and localization of voltage dependent potassium channel Kv4.2 in epilepsy associated focal lesions,” Neurobiology of Disease, vol. 36, no. 1, pp. 81–95, 2009. View at: Publisher Site | Google Scholar
  19. K. Ohno and M. Higashima, “Effects of antiepileptic drugs on afterdischarge generation in rat hippocampal slices,” Brain Research, vol. 924, no. 1, pp. 39–45, 2002. View at: Publisher Site | Google Scholar
  20. S. Yamaguchi and M. A. Rogawski, “Effects of anticonvulsant drugs on 4-aminopyridine-induced seizures in mice,” Epilepsy Research, vol. 11, no. 1, pp. 9–16, 1992. View at: Publisher Site | Google Scholar
  21. E. C. Cooper, “Potassium channels: how genetic studies of epileptic syndromes open paths to new therapeutic targets and drugs,” Epilepsia, vol. 42, supplement 5, pp. 49–54, 2001. View at: Google Scholar
  22. B. S. Meldrum and M. A. Rogawski, “Molecular targets for antiepileptic drug development,” Neurotherapeutics, vol. 4, no. 1, pp. 18–61, 2007. View at: Publisher Site | Google Scholar
  23. J. M. Bekkers, “Distribution and activation of voltage-gated potassium channels in cell-attached and outside-out patches from large layer 5 cortical pyramidal neurons of the rat,” Journal of Physiology, vol. 525, part 3, pp. 611–620, 2000. View at: Google Scholar
  24. Z. W. Liu, T. Lei, T. Zhang, and Z. Yang, “Peroxynitrite donor impairs excitability of hippocampal CA1 neurons by inhibiting voltage-gated potassium currents,” Toxicology Letters, vol. 175, no. 1–3, pp. 8–15, 2007. View at: Publisher Site | Google Scholar
  25. G. Maccaferri and C. J. McBain, “Passive propagation of LTD to stratum oriens-alveus inhibitory neurons modulates the temporoammonic input to the hippocampal CA1 region,” Neuron, vol. 15, no. 1, pp. 137–145, 1995. View at: Google Scholar
  26. M. Borde, J. R. Cazalets, and W. Buno, “Activity-dependent response depression in rat hippocampal CA1 pyramidal neurons in vitro,” Journal of Neurophysiology, vol. 74, no. 4, pp. 1714–1729, 1995. View at: Google Scholar
  27. D. S. Shin, W. Yu, A. Sutton, M. Calos, E. Puil, and P. L. Carlen, “Isovaline, a rare amino acid, has anticonvulsant properties in two in vitro hippocampal seizure models by increasing interneuronal activity,” Epilepsia, vol. 52, no. 11, pp. 2084–2093, 2011. View at: Publisher Site | Google Scholar
  28. J. J. Duan, Q. Wang, C. Y. Deng, S. J. Kuang, R. Z. Chen, and L. Tao, “Effects of carvedilol on delayed rectifier and transient inactivating potassium currents in rat hippocampal CA1 neurons,” Clinical and Experimental Pharmacology and Physiology, vol. 37, no. 10, pp. 996–1003, 2010. View at: Publisher Site | Google Scholar
  29. V. Riazanski, A. Becker, J. Chen et al., “Functional and molecular analysis of transient voltage-dependent K+ currents in rat hippocampal granule cells,” Journal of Physiology, vol. 537, part 2, pp. 391–406, 2001. View at: Publisher Site | Google Scholar
  30. A. E. Watts and J. G. R. Jefferys, “Effects of carbamazepine and baclofen on 4-aminopyridine-induced epileptic activity in rat hippocampal slices,” British Journal of Pharmacology, vol. 108, no. 3, pp. 819–823, 1993. View at: Google Scholar
  31. P. P. Quilichini, D. Diabira, C. Chiron, M. Milh, Y. Ben-Ari, and H. Gozlan, “Effects of antiepileptic drugs on refractory seizures in the intact immature corticohippocampal formation in vitro,” Epilepsia, vol. 44, no. 11, pp. 1365–1374, 2003. View at: Publisher Site | Google Scholar
  32. C. Brückner and U. Heinemann, “Effects of standard anticonvulsant drugs on different patterns of epileptiform discharges induced by 4-aminopyridine in combined entorhinal cortex-hippocampal slices,” Brain Research, vol. 859, no. 1, pp. 15–20, 2000. View at: Publisher Site | Google Scholar
  33. S. G. Birnbaum, A. W. Varga, L. L. Yuan, A. E. Anderson, J. D. Sweatt, and L. A. Schrader, “Structure and function of Kv4-family transient potassium channels,” Physiological Reviews, vol. 84, no. 3, pp. 803–833, 2004. View at: Publisher Site | Google Scholar
  34. M. Menegola, H. Misonou, H. Vacher, and J. S. Trimmer, “Dendritic A-type potassium channel subunit expression in CA1 hippocampal interneurons,” Neuroscience, vol. 154, no. 3, pp. 953–964, 2008. View at: Publisher Site | Google Scholar
  35. T. Falk, R. K. Kilani, L. A. Strazdas et al., “Developmental regulation of the A-type potassium-channel current in hippocampal neurons: role of the Kvβ1.1 subunit,” Neuroscience, vol. 120, no. 2, pp. 387–404, 2003. View at: Publisher Site | Google Scholar
  36. C. Rüschenschmidt, R. Köhling, M. Schwarz et al., “Characterization of a fast transient outward current in neocortical neurons from epilepsy patients,” Journal of Neuroscience Research, vol. 75, no. 6, pp. 807–816, 2004. View at: Publisher Site | Google Scholar
  37. E. Fransén and J. Tigerholm, “Role of A-type potassium currents in excitability, network synchronicity, and epilepsy,” Hippocampus, vol. 20, no. 7, pp. 877–887, 2010. View at: Publisher Site | Google Scholar
  38. O. O. Luk'ianets' and V. A. Iavors'kyi, “The action of pilocarpine on the accommodation properties of isolated phasic neurons of the rat hippocampus,” Fiziolohichnyi zhurnal, vol. 45, no. 4, pp. 35–40, 1999. View at: Google Scholar
  39. M. M. Monaghan, M. Menegola, H. Vacher, K. J. Rhodes, and J. S. Trimmer, “Altered expression and localization of hippocampal A-type potassium channel subunits in the pilocarpine-induced model of temporal lobe epilepsy,” Neuroscience, vol. 156, no. 3, pp. 550–562, 2008. View at: Publisher Site | Google Scholar
  40. C. Bernard, A. Anderson, A. Becker, N. P. Poolos, H. Deck, and D. Johnston, “Acquired dendritic channelopathy in temporal lobe epilepsy,” Science, vol. 305, no. 5683, pp. 532–535, 2004. View at: Publisher Site | Google Scholar
  41. N. N. Urban and G. Barrionuevo, “Active summation of excitatory postsynaptic potentials in hippocampal CA3 pyramidal neurons,” Proceedings of the National Academy of Sciences of the United States of America, vol. 95, no. 19, pp. 11450–11455, 1998. View at: Publisher Site | Google Scholar
  42. G. M. Ramakers and J. F. Stormt, “A postsynaptic transient K+ current modulated by arachidonic acid regulates synaptic integration and threshold for LTP induction in hippocampal pyramidal cells,” Proceedings of the National Academy of Sciences of the United States of America, vol. 99, no. 15, pp. 10144–10149, 2002. View at: Publisher Site | Google Scholar
  43. C. Zona, V. Tancredi, P. Longone et al., “Neocortical potassium currents are enhanced by the antiepileptic drug lamotrigine,” Epilepsia, vol. 43, no. 7, pp. 685–690, 2002. View at: Publisher Site | Google Scholar
  44. H. Grunze, R. W. Greene, H. J. Möller, T. Meyer, and J. Walden, “Lamotrigine may limit pathological excitation in the hippocampus by modulating a transient potassium outward current,” Brain Research, vol. 791, no. 1-2, pp. 330–334, 1998. View at: Publisher Site | Google Scholar
  45. J. Walder, U. Altrup, H. Reith, and E. J. Speckmann, “Effects of valproate on early and late potassium currents of single neurons,” European Neuropsychopharmacology, vol. 3, no. 2, pp. 137–141, 1993. View at: Publisher Site | Google Scholar
  46. C. Zona, V. Tancredi, E. Palma, G. C. Pirrone, and M. Avoli, “Potassium currents in rat cortical neurons in culture are enhanced by the antiepileptic drug carbamazepine,” Canadian Journal of Physiology and Pharmacology, vol. 68, no. 4, pp. 545–547, 1990. View at: Google Scholar
  47. A. Korngreen and B. Sakmann, “Voltage-gated K+ channels in layer 5 neocortical pyramidal neurones from young rats: subtypes and gradients,” Journal of Physiology, vol. 525, part 3, pp. 621–639, 2000. View at: Google Scholar

Copyright © 2013 Wei Xie et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

More related articles

1060 Views | 965 Downloads | 6 Citations
 PDF Download Citation Citation
 Download other formatsMore
 Order printed copiesOrder

Related articles

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.